Printer Friendly

QUANTECH LTD. AND ANTIVIRALS INC. ENTER INTO A R&D AGREEMENT

 ST. PAUL, Minn., July 27 /PRNewswire/ -- Quantech Ltd. (NASDAQ: QQQQ), a publicly held diagnostic company working in the field of biosensor diagnostics, announced today that it has executed a research and development agreement with the privately owned AntiVirals Inc. of Portland, Ore. The objective of the joint agreement is to apply AntiVirals unique antisense compounds to Quantech's SPR technology. The proven application of SPR to gene probe assays will now be greatly enhanced by the use of AntiVirals novel, stable, highly specific antisense compounds.
 AntiVirals, Inc., is the pioneer company in the Antisense field and has developed unique and patented methods of providing genetically based pharmaceutical agents. These agents, called Neu-Genes, interfere with the activity of infectious agents, disabling them at the genetic level. Neu-Genes are a novel synthetic polymers that overcome most of the problems associated with modified, natural Antisense agents. Indications for these agents are extensive and include applications to infectious diseases, inflammation, genetic screening and cancer.
 Employing these novel agents with the SPR Systems of Quantech Ltd. will marry two key advanced technologies that will result in a diagnostic system constituting the next generation of gene probe technology and provide advanced diagnostic systems to address a wide range of research and clinical situations.
 Quantech Ltd. is in discussions with a number of diagnostics companies whom have the ability to fully exploit the potential of this new development. The evaluation will begin within the next thirty days.
 -0- 7/27/93
 /CONTACT: Jill Miller, co. relations mgr. of Quantech, 612-647-6370/
 (QQQQ)


CO: Quantech, Inc.; AntiVirals, Inc. ST: Minnesota; Oregon IN: MTC SU: TNM

TJ -- MN025 -- 6483 07/27/93 17:49 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:274
Previous Article:AIRTRAN CORPORATION REPORTS FIRST QUARTER EARNINGS
Next Article:GRAND CASINOS REPORTS EARNINGS PER SHARE OF $0.18 FOR THE SIX MONTHS ENDED JULY 4 AND FILING OF REGISTRATION STATEMENT FOR PUBLIC OFFERING
Topics:


Related Articles
ESTELLE APPOINTED AS CHAIRMAN OF THE BOARD OF QUANTECH LTD.
QUANTECH ANNOUNCES RESEARCH PACT WITH U.S. NAVY
QUANTECH ANNOUNCES NEW DIRECTORS
QUANTECH ANNOUNCES FIRST SALE
Quantech Announces That Its Stock No Longer Subject to Penny Stock Rules
Quantech Ltd. Announces Registration Statement Has Been Declared Effective
Quantech Announces Amendment to Serono Licensing Agreement
Quantech Ltd. Announces Development Agreement.
Quantech Ltd. and Mitsubishi Chemical Corporation Sign System Technology Evaluation Agreement.
Quantech Ltd. and Mitsubishi Chemical Corporation Expand Relationship.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters